Overview

Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler

Status:
Completed
Trial end date:
2019-05-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by dry powder inhaler (DPI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Phase:
Phase 2
Details
Lead Sponsor:
Verona Pharma plc
Collaborator:
Iqvia Pty Ltd